Home > Analytics > SYNCOM FORMULATIONS (INDIA)

SYNCOM FORMULATIONS (INDIA)
Intrinsic Value | Fundamental Analysis

BOM : 524470     NSE : SYNCOMF    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward
Pledged Shares : None or < 25%
Feb 28,2025
Price(EOD): ₹ 15.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 1,442.90 Cr
Value of ₹ 1 Lac invested in SYNCOM FORMULATIONS (INDIA)
on Mar 02,2020 (price: ₹ 0.65)

₹ 1 L

₹ 23.62 L

1W : -9.7% 1M : -13% 1Y : 7.7%
COMMUNITY POLL
for SYNCOM FORMULATIONS (INDIA)
Please provide your vote to see the results
SYNCOM FORMULATIONS (INDIA) is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
Industry Peers & Returns1W1M1Y
SYNCOM FORMULATIONS (INDIA) -9.7% -13% 7.7%
SUN PHARMACEUTICAL INDUSTRIES -3% -8.7% 4.1%
DIVIS LABORATORIES -4.7% -4.5% 58.5%
CIPLA -4.3% -3.2% -3.2%
TORRENT PHARMACEUTICALS -3% -12.3% 13.8%
DR REDDYS LABORATORIES -3% -6.5% -12.7%
MANKIND PHARMA -1.6% -8% 9.4%
ZYDUS LIFESCIENCES -1% -8.1% -5.9%
LUPIN NA -7.7% 16.6%

FUNDAMENTAL ANALYSIS OF SYNCOM FORMULATIONS (INDIA)

 
Fundamentals Score
[ Q(TTM): Dec2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF SYNCOM FORMULATIONS (INDIA)

 
Valuation Score
[As on : Feb 28,2025 ]

Ratio Consolidated
P/E
P/B
P/S
36.86
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 39.15 Cr
[Latest Qtr - Dec2024 - Consolidated Results ]

5.01
P/B Calculated based on Book Value of Rs 288.14 Cr
[Latest Year - Mar2024 - Consolidated Results ]

3.68
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 391.68 Cr
[Latest Qtr - Dec2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 23% undervalued companies ! Discover More →

FAIR VALUE OF SYNCOM FORMULATIONS (INDIA)

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
70%
-16%
-14%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SYNCOM FORMULATIONS (INDIA)



SYNCOM FORMULATIONS (INDIA) vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SYNCOM FORMULATIONS (INDIA)

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0.25
0.32
0.27
0.28
0.25
0.32
0.27
0.28
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SYNCOM FORMULATIONS (INDIA)

Pledged Promoter Shares
0 %
As on : Dec2024

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SYNCOM FORMULATIONS (INDIA)

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
24.65%
21.12%
16.24%
17.04%
95.78%
100.16%
84.37%
85.65%
QtrlyTrend
8
Latest Qtr: Dec2024
Quarterly Result Analysis →


SYNCOM FORMULATIONS (INDIA) related INDICES

BSE Indices1W1M1Y
BSE ALLCAP -2.1% -3.2% -0.6%
BSE HEALTHCARE -5.1% -7.1% 7.7%
BSE MIDSMALLCAP -6% -10.6% -4.7%
BSE SMALLCAP -6.5% -12.2% -6.4%
No NSE index found

You may also like the below Video Courses


FAQ about SYNCOM FORMULATIONS (INDIA)


Is SYNCOM FORMULATIONS (INDIA) good for long term investment?

As on Feb 28,2025, the Fundamentals of SYNCOM FORMULATIONS (INDIA) look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SYNCOM FORMULATIONS (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SYNCOM FORMULATIONS (INDIA) UnderValued or OverValued?

As on Feb 28,2025, SYNCOM FORMULATIONS (INDIA) is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!

What is the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) ?

As on Feb 28,2025, the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) is Rs. 17.84 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 9.02
Fair Value [Median EV / Sales Model] : Rs. 18.28
Fair Value [Median Price / Sales Model] : Rs. 17.84
Estimated Median Fair Value of SYNCOM FORMULATIONS (INDIA) : Rs. 17.84

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is SYNCOM FORMULATIONS (INDIA) trading at a Premium or Discount?

As on Feb 28,2025, SYNCOM FORMULATIONS (INDIA) is trading at a Discount of -14% based on the estimates of Median Intrinsic Value!